Careers  |  Sign In  |  Register  |   Twitter

H3 receptor antagonist may help relieve allergic rhinitis symptoms

Reuters Health • The Doctor's Channel Daily Newscast

NEW YORK (Reuters Health) – The effects of an H1 receptor antagonist in reducing allergen-induced nasal symptoms appear to be enhanced with the addition of an H3 receptor antagonist, according to the results of a challenge study reported online December 26 in the Journal of Allergy and Clinical Immunology.

As a summary of the clinical implications states, “Second-generation H1 receptor antagonists improve most symptoms of allergic rhinitis except nasal congestion.  An oral H3 receptor antagonist decreased nasal congestion with an oral H1 receptor antagonist.”

The study, sponsored by Pfizer, used a randomized, double-blind, double-dummy, placebo-controlled, 4-way crossover design to investigate the effect of adding an investigational H3 antagonist designated PF-03654746 to fexofenadine in 20 patients with out-of-season allergic rhinitis.

Dr. Thomas B. Casale, at Creighton University in Omaha, Nebraska, and colleagues assigned the participants in random order to treatment with 10 mg of PF-03654746 + 60 mg of fexofenadine, 1 mg of PF-03654746 + 60 mg of fexofenadine, 60 mg of fexofenadine + 120 mg of pseudoephedrine, and placebo with at least 10 days between study periods.

The effect of a single dose of study medication on minimum nasal cross-sectional area and nasal volume after ragweed challenge was measured with acoustic rhinometry, and participants reported nasal symptoms of congestion, itching, and rhinorrhea on a 0- to 5-point scale.

The 10 mg of PF-03654746 plus fexofenadine dose significantly decreased the nasal congestion symptoms compared with placebo (-0.7; p=0.011), the investigators report.  It also showed statistically significant effects on all other symptom scores versus placebo.

The effect of the 1 mg of PF-03654746 plus fexofenadine dose was also significant versus placebo for itching, rhinorrhea, and sneeze count, the data indicate.  Fexofenadine/pseudoephedrine versus placebo had a statistically significant effect for rhinorrhea and sneeze count.

“In combination with fexofenadine, single doses of PF-03654746 caused a reduction in allergen-induced nasal symptoms,” the researchers conclude.  “H3 receptor antagonism might be a novel therapeutic strategy to further explore in patients with allergic rhinitis.”

SOURCE:

The effects of an H3 receptor antagonist (PF-03654746) with fexofenadine on reducing allergic rhinitis symptoms. J Allergy Clin Immunol 2012.